TARSUS PHARMACEUTICALS, INC. Increase (Decrease) in Prepaid Expense
TARSUS PHARMACEUTICALS, INC. (TARS) reported Increase (Decrease) in Prepaid Expense of -$3.86 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidExpense · last filed 2026-08-06
- TARSUS PHARMACEUTICALS, INC. increase (decrease) in prepaid expense for the quarter ending 2026-06-30 was -$17.11M, a 173.81% decline year-over-year.
- TARSUS PHARMACEUTICALS, INC. increase (decrease) in prepaid expense for the quarter ending 2026-03-31 was $13.24M.
- TARSUS PHARMACEUTICALS, INC. increase (decrease) in prepaid expense for the quarter ending 2025-12-31 was -$8.19M, a 206.30% decline year-over-year.
- TARSUS PHARMACEUTICALS, INC. increase (decrease) in prepaid expense for the quarter ending 2025-09-30 was -$7.98M, a 794.34% decline year-over-year.
- TARSUS PHARMACEUTICALS, INC. increase (decrease) in prepaid expense for fiscal 2025 was -$1.72M, a 124.45% decline from fiscal 2024.
- TARSUS PHARMACEUTICALS, INC. increase (decrease) in prepaid expense for fiscal 2024 was $7.02M, a 142.96% increase from fiscal 2023.
- TARSUS PHARMACEUTICALS, INC. increase (decrease) in prepaid expense for fiscal 2023 was $2.89M, a 300.69% increase from fiscal 2022.
- TARSUS PHARMACEUTICALS, INC. increase (decrease) in prepaid expense for fiscal 2022 was $721.00K.
| Period end | Increase (Decrease) in Prepaid Expense 3 month | Increase (Decrease) in Prepaid Expense 6 month | Increase (Decrease) in Prepaid Expense 9 month | Increase (Decrease) in Prepaid Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$17.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$3.86M 10-Q · filed 2026-08-06 | -$12.05M derived: sum of 3 quarters · filed 2026-08-06 | -$20.03M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $13.24M 10-Q · filed 2026-05-06 | $5.06M derived: sum of 2 quarters · filed 2026-05-06 | -$2.92M derived: sum of 3 quarters · filed 2026-05-06 | $20.25M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$8.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$16.16M derived: sum of 2 quarters · filed 2026-02-23 | $7.01M derived: sum of 3 quarters · filed 2026-08-06 | -$1.72M 10-K · filed 2026-02-23 |
| 2025-09-30 | -$7.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $15.20M derived: sum of 2 quarters · filed 2026-08-06 | $6.47M 10-Q · filed 2025-11-04 | $14.17M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $23.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $14.45M 10-Q · filed 2026-08-06 | $22.15M derived: sum of 3 quarters · filed 2026-08-06 | $23.30M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$8.72M 10-Q · filed 2026-05-06 | -$1.02M derived: sum of 2 quarters · filed 2026-05-06 | $126.00K derived: sum of 3 quarters · filed 2026-05-06 | -$641.00K derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $7.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $8.85M derived: sum of 2 quarters · filed 2026-02-23 | $8.08M derived: sum of 3 quarters · filed 2026-02-23 | $7.02M 10-K · filed 2026-02-23 |
| 2024-09-30 | $1.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $382.00K derived: sum of 2 quarters · filed 2025-11-04 | -$683.00K 10-Q · filed 2025-11-04 | $1.18M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-06-30 | -$767.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$1.83M 10-Q · filed 2025-08-06 | $29.00K derived: sum of 3 quarters · filed 2026-02-23 | $822.00K derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-03-31 | -$1.06M 10-Q · filed 2025-05-01 | $796.00K derived: sum of 2 quarters · filed 2026-02-23 | $1.59M derived: sum of 3 quarters · filed 2026-02-23 | $2.08M derived: sum of 4 quarters · filed 2026-02-23 |
| 2023-12-31 | $1.86M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $2.65M derived: sum of 2 quarters · filed 2026-02-23 | $3.15M derived: sum of 3 quarters · filed 2026-02-23 | $2.89M 10-K · filed 2026-02-23 |
| 2023-09-30 | $793.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $1.28M derived: sum of 2 quarters · filed 2024-11-13 | $1.03M 10-Q · filed 2024-11-13 | $2.30M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $492.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $235.00K 10-Q · filed 2024-08-08 | $1.51M derived: sum of 3 quarters · filed 2025-02-25 | $702.00K derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | -$257.00K 10-Q · filed 2024-05-08 | $1.01M derived: sum of 2 quarters · filed 2025-02-25 | $210.00K derived: sum of 3 quarters · filed 2025-02-25 | $1.39M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $1.27M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $467.00K derived: sum of 2 quarters · filed 2025-02-25 | $1.65M derived: sum of 3 quarters · filed 2025-02-25 | $721.00K 10-K · filed 2025-02-25 |
| 2022-09-30 | -$805.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $375.00K derived: sum of 2 quarters · filed 2023-11-09 | -$551.00K 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $1.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $254.00K 10-Q · filed 2023-08-10 | ||
| 2022-03-31 | -$926.00K 10-Q · filed 2023-05-09 | |||
| 2021-09-30 | $663.00K 10-Q · filed 2022-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |